Clinical experience with gefitinib in Indian patients.
Parikh, Purvish Chang, Alex Nag, Shona Digumarti, Raghunadharao Bhattacharyya, Gouri Shankar Doval, Dinesh Chandra Babu, Govind Chacko, Raju Titus Advani, Suresh Ranade, Anantbhushan
Parikh, Purvish
Chang, Alex
Nag, Shona
Digumarti, Raghunadharao
Bhattacharyya, Gouri Shankar
Doval, Dinesh Chandra
Babu, Govind
Chacko, Raju Titus
Advani, Suresh
Ranade, Anantbhushan
Citations
Altmetric:
Abstract
INTRODUCTION: Treatment options are limited in patients with advanced or refractory non-small cell lung cancer and lead to suboptimal outcome and/or benefit. The epidermal growth factor tyrosine kinase inhibitor gefitinib (IRESSA) has been approved in many countries. Increased responsiveness to gefitinib has been demonstrated in particular subsets of patients, for example never smokers and patients of Asian origin. However, to date, little is known of its use specifically in patients from India. METHODS: Retrospective ad hoc analysis of clinical data from experience with gefitinib in patients with advanced NSCLC from India enrolled in the IRESSA Survival Evaluation in Lung (ISEL) study (n = 77) or included in the gefitinib expanded-access program in India (n = 133). RESULTS: Among Indian patients enrolled in the ISEL study, median survival was 6.4 months with gefitinib and 5.1 month with placebo. The objective response rate in Indian patients was 14% with gefitinib versus 0% with placebo. In ISEL, tolerability data from Indian patients were consistent with the overall study population. In the Indian gefitinib expanded-access program, median survival was 6 months and gefitinib was well tolerated. CONCLUSIONS: Gefitinib seems well tolerated in Indian patients with advanced NSCLC, with some clinical benefit observed.
Description
Date
2008-04
Publisher
Collections
Keywords
Lung Cancer
Randomized Controlled Trial
Non-Small-Cell Lung Cancer
Randomized Controlled Trial
Non-Small-Cell Lung Cancer
Type
Article
Citation
Clinical experience with gefitinib in Indian patients. 2008, 3 (4):380-5 J Thorac Oncol